GlassScriptPhysician profile
Stephanie Gallagher
NPI 1790152064
$2,510.67
in general payments reported to CMS, 2019-2025
25 companies · $914 in 2025
The $914 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.99 · 2022: $245 · 2023: $1,054 · 2024: $287 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $397.30 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $277.74 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.43 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $187.03 | 2022-2025 | Verquvo |
| Gilead Sciences, INC. | $146.67 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $130.55 | 2023-2025 | Farxiga, Brilinta, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.50 | 2023-2025 | Lifevest |
| Medtronic, INC. | $121.78 | 2023 | Azure Xt Dr Mri Surescan, Linq II |
| Boston Scientific Corporation | $99.11 | 2022-2023 | Watchman Flx, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $95.64 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $89.70 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $79.71 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $66.02 | 2022-2025 | Camzyos |
| Edwards Lifesciences Corporation | $63.05 | 2024-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $56.88 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $54.51 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $49.24 | 2023 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $46.10 | 2022-2023 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $33.78 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $30.03 | 2025 | Attruby |
| Abiomed | $23.17 | 2025 | |
| Novo Nordisk INC | $18.91 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.70 | 2025 | Amvuttra |
| Glaxosmithkline, LLC. | $14.72 | 2025 | Arexvy |
| Esperion Therapeutics, INC. | $14.40 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.